2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This, alongside the risk of adverse events, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!